N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Cardiac Amyloidosis Discovery Trial
Cardiac Amyloidosis
Primary: Rate of Cardiac Amyloidosis Diagnosis — 24 Participants
Phase 2 N=17 Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: Change in Inflammation Marker — -43; 7 mg/L
N/A N=94 Cardiac Rehabilitation Peer Mentorship
Percutaneous Coronary Intervention · Coronary Artery Bypass Graft Surgery, With or Without Valve Surgery · Acute Coronary Syndrome
Primary: Cardiac Rehabilitation Enrollment — 20; 15 participants
N/A N=677 Unexpected Cardiac Arrest in Intensive Care Unit
Heart Arrest
Primary: Number of Patients With Unexpected Cardiac Arrest — 677; 30,722 Participants
N/A N=76 Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia
Ventricular Tachycardia
Primary: Number of Subjects Without Hospitalization for Ventricular Tachycardia (VT) During 6 Months — 38 Participants
Phase 2 N=59 Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias
Premature Atrial Contraction
Primary: Change in Premature Atrial Contractions (PACs) — -0.6; -5.6 Episodes/hour
N/A N=96 Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac Allograft Vasculopathy
Primary: Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year — 3.39; 3.65 mm3/mm
N/A N=61 Increasing Adherence to Treatment Recommendations Following a Cardiac Event
Cardiovascular Disease
Primary: Participation in CR — 7; 11; 6 Participants
N/A N=182 Scripps Wired for Health Monitoring Study
Diabetes · Hypertension · Cardiac Arrhythmia
Primary: Participant Perceptions of Utility of Monitoring — 13.4; 11.3 Score on a scale
N/A N=34 Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery
Congenital Heart Defects
Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2
Phase 4 N=50 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method
Arrhythmia, Cardiac · Kidney Cancer · Surgery
Primary: Incidence of Perioperative Cardiac Arrhythmias Evaluated by a Continuous ECG Holter Monitoring in the Perioperative Period — 6; 6; 18; 16 Participants — p=0.3861
Phase 2 N=15 Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents
Duchenne Muscular Dystrophy
Primary: Pharmacokinetics Outcome: Absolute Values of (+)-Epicatechin Serum Concentration, Pre-dose (Trough) and 2 Hours Post-dose (Peak) — 15.1; 33.9; 20.6; 481.2 nM — p=0.0482
N/A N=75 VItamin D Metabolism in SEnescent Cardiac Surgery Patients
Coronary Artery Bypass Grafting · Heart Valve Surgery
Primary: Peri- and Postoperative Time Course of Circulating 1,25-dihydroxyvitamin D in the First Postoperative Month in Cardiac Surgery Patients — 13; 4.2 percentage
N/A N=19 Robotic Cardiac Surgery Wet Lab Simulation Study
Robotic Cardiac Surgery Simulation
Primary: Time-based Score — 553; 127; 143 score on a scale